Roche to introduce ‘cobas® pulse’ cardiovascular disease diagnostic platform
“Entering the market with a proven platform adoption model”
Synergy expected with existing sales network for community clinics
Same-day testing and diagnosis of HbA1c and more via finger-prick blood sampling
HK inno.N Square. Provided by HK inno.N
HK inno.N announced on the 2nd that it has signed a sales agreement with Roche Diagnostics Korea for the next-generation Point of Care Testing (POCT) platform “cobas click.” Through this agreement, the company has made a full-fledged entry into the medical device market.
Under the agreement, HK inno.N will be responsible for domestic sales and distribution of cobas click. The company plans to leverage the sales capabilities it has built through its existing prescription drug business to expand into the medical device sector. HK inno.N will begin full-scale sales of cobas click this month, with plans to expand its presence in the growing chronic disease management market.
cobas click is an integrated diagnostic platform that enables rapid on-site testing—without outsourcing to external laboratories—for glycated hemoglobin (HbA1c), lipids, and C-reactive protein (CRP), which are essential for diabetes and cardiovascular disease management. A key feature is that it allows healthcare professionals to assess a patient’s blood glucose control status and cardiovascular risk at once with just a fingertip blood sample. The platform is expected to significantly improve convenience in related clinical practice.
HK inno.N emphasized that, in particular, cobas click offers a high level of concordance with central laboratory test results, supported by differentiated technological capabilities. The HbA1c test is designed to minimize interference from variant hemoglobin, while the lipid test incorporates an algorithm that reduces potential triglyceride measurement errors during the testing process, thereby enhancing the reliability of results.
Product image of Roche Diagnostics Korea’s Point of Care Testing platform cobas click, distributed and sold in Korea by HK inno.N. Provided by HK inno.N
According to HK inno.N, the demand for in-clinic testing at primary care institutions has been increasing recently due to population aging and the growing number of patients with chronic diseases. In the case of cobas click, in addition to ease of use, reagents can be stored at room temperature and preserved for long periods (up to 16 months), enabling efficient operation. HK inno.N’s strategy is to build market competitiveness centered on primary care institutions by capitalizing on these strengths.
Gwak Dal-won, CEO of HK inno.N, said, “We have taken our first step into the medical device business through cobas click, a next-generation integrated diagnostic platform,” adding, “By providing rapid and accurate diagnostic results with a single blood draw, we will enhance diagnostic convenience at primary care institutions and contribute to effective disease management for patients.”
Under this agreement, HK inno.N has taken its initial step into the market not by developing its own medical devices from scratch, but by adopting and distributing a proven platform. The company has chosen to collaborate with Roche, a global leader in the diagnostic device market, as a way to reduce risks associated with astronomical research and development costs. Industry observers expect this strategy to generate strong synergies with HK inno.N’s solid domestic medical institution network, built through the sales of the gastroesophageal reflux disease drug “K-CAB” and a diverse portfolio of cardiovascular and diabetes treatments. In particular, at community clinics, where drawing blood for diagnostic purposes typically involves sending samples to external laboratories and waiting several days for results, the ability to perform immediate testing is expected to significantly improve both the speed and convenience of care.
ⓒ dongA.com. All rights reserved. Reproduction, redistribution, or use for AI training prohibited.
Popular News